Influence high-dose aprotinin treatment blood loss coagulation patterns patients myocardial revascularization Intraoperative administration proteinase inhibitor aprotinin reduction blood loss homologous blood requirement patients undergoing cardiac surgery blood-saving effect aprotinin information mode action patients undergoing primary myocardial revascularization aprotinin placebo treatment Aprotinin bolus kallikrein inactivator units KIU surgery continuous infusion KIU/h surgery KIU pump prime Strict criteria homogeneous patient selection Total blood loss ml control group ml aprotinin group homologous blood requirement ml ml control group homologous blood blood products aprotinin group Twenty-five percent patients control group aprotinin group blood homologous blood products activated clotting time indicator inhibition contact phase coagulation heparinization aprotinin group heparin cardiopulmonary bypass CPB 